Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Open-Label Study, to Evaluate the Feasibility and Safety of Intravenous [99mTc]Tc-PSMA-T4 in Subjects With Prostate Cancer

NCT05847166 is registered in ClinicalTrials.gov with NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom as lead sponsor.

NCT NCT05847166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05847166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Open-Label Study, to Evaluate the Feasibility and Safety of Intravenous [99mTc]Tc-PSMA-T4 in Subjects With Prostate Cancer
Lead sponsor
NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom
Phase
Not applicable
Overall status
Recruiting
Start date
May 10, 2023
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer